Lecturer of Ophthalmology, Department of Ophthalmology, Mansoura Ophthalmic Center, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Associate Professor of Ophthalmology, Department of Ophthalmology, Mansoura Ophthalmic Center, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Eye (Lond). 2022 Nov;36(11):2137-2143. doi: 10.1038/s41433-021-01814-5. Epub 2021 Oct 28.
To assess reactivation after initial intravitreal injection of ranibizumab (IVR) for type 1 retinopathy of prematurity (ROP) or worse and the outcome following reinjection of ranibizumab for this reactivation.
This retrospective study was performed on infants screened for ROP between March 2013 and February 2020 in Mansoura University Children Hospital, Mansoura, Egypt. Infants treated with ranibizumab 0.25 mg/0.025 mL were identified for review of their clinical outcomes. Data of infants with reactivation and IVR re-injection were analysed.
A total of 2318 infants were screened for ROP, 115 (5%) infants (216 eyes) with a mean gestational age of 30 ± 2.5 weeks and mean birth weight of 1290 ± 355.2 g received IVR at mean postmenstrual age (PMA) of 38 ± 3.1 weeks. All treated eyes demonstrated initial regression of ROP. However, ROP reactivation occurred in 5 (2.3%) eyes of 3 patients, at an average of 9.6 ± 2.9 weeks after treatment. None of these eyes had retinal detachment. A second dose IVR was administered and all five eyes showed regression with complete retinal vascularisation, at a mean PMA of 60 ± 5.1 weeks.
IVR is beneficial as an initial and subsequent treatment for type 1 ROP or APROP. A long-term follow-up until complete retinal vascularisation is recommended to avoid disease reactivation.
评估初始玻璃体内注射雷珠单抗（IVR）治疗 1 型早产儿视网膜病变（ROP）或更严重病变后的再激活情况，以及针对这种再激活进行雷珠单抗再注射的结果。
本回顾性研究纳入了 2013 年 3 月至 2020 年 2 月在埃及曼苏拉大学儿童医院接受 ROP 筛查的婴儿。对接受雷珠单抗 0.25mg/0.025mL 治疗的婴儿进行了复查，以评估其临床结果。分析了有再激活和 IVR 再注射的婴儿的数据。
共筛查了 2318 例婴儿的 ROP，其中 115 例（5%）婴儿（216 只眼）的平均胎龄为 30±2.5 周，平均出生体重为 1290±355.2g，在平均孕龄（PMA）38±3.1 周时接受 IVR 治疗。所有接受治疗的眼睛均显示 ROP 初始消退。然而，在 3 名患者的 5 只眼中（2.3%）出现 ROP 再激活，平均在治疗后 9.6±2.9 周。这些眼中均未发生视网膜脱离。给予第二剂量 IVR 治疗，所有 5 只眼均显示出消退，完全视网膜血管化，平均 PMA 为 60±5.1 周。
IVR 作为 1 型 ROP 或 APROP 的初始和后续治疗是有益的。建议进行长期随访，直至完全视网膜血管化，以避免疾病再激活。
